Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate
S Calleja1, J Salas-Puig, R Ribacoba
1Neurological Department, Hospital General de Asturias, Oviedo, Spain. jsalasp@meditex.es
Insights
Sodium valproate (VPA) effectively controls seizures in juvenile myoclonic epilepsy (JME). However, discontinuing VPA therapy leads to high relapse rates, suggesting JME may require lifelong treatment.
Area of Science:
- Neurology
- Pharmacology
- Epilepsy Research
Background:
- Juvenile myoclonic epilepsy (JME) is a common epilepsy syndrome.
- Sodium valproate (VPA) is the established first-line treatment for JME.
Purpose of the Study:
- To evaluate the long-term efficacy and outcomes of VPA monotherapy in JME patients.
- To assess relapse rates following VPA discontinuation in JME.
Main Methods:
- Retrospective analysis of 22 JME patients treated with VPA monotherapy from the outset.
- Inclusion criteria: unequivocal JME diagnosis, VPA monotherapy initiation, and >5 years follow-up.
- EEG recordings were analyzed, and patient outcomes were tracked.
Main Results:
- VPA controlled seizures in 80% of patients.
- All patients continuing VPA treatment remained seizure-free.
- Four patients required add-on therapy (lamotrigine or clobazam) for persistent seizures.
- Discontinuation of VPA therapy resulted in a high rate of seizure relapse.
Conclusions:
- Sodium valproate is highly effective for controlling seizures in JME.
- Lifelong VPA therapy may be necessary for sustained seizure control in JME.
- Accurate diagnosis and appropriate VPA therapy are crucial for managing JME.
Abstract:
Sodium valproate (VPA) is considered the first choice drug in juvenile myoclonic epilepsy (JME). We have analysed the long-term evolution of 22 patients treated from the outset with VPA. The following inclusion criteria were applied: (1) unequivocal diagnosis of JME; (2) treatment should be initiated with VPA monotherapy; and (3) follow-up for more than 5 years. Twenty-two patients (15 females, seven males) were studied and their EEG recordings were analysed. Their mean age was 28 years (range: 20-40 years) and their mean follow-up was 7.7 years (range: 5-17 years). Four of them suffered persistent seizures despite optimal VPA dosage and needed the addition of a second drug (lamotrigine in three cases, clobazam in one case). All of our patients who continued their treatment are seizure-free. VPA effectively controlled all seizures in 80% of patients. The discontinuation of drug therapy lead to a very high rate of relapses. With accurate diagnosis and appropriate therapy, seizures in JME can be effectively controlled. VPA is a very effective antiepileptic drug in controlling the seizures of JME, but many patients relapse after VPA discontinuation. Thus, JME may require lifelong therapy.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:13Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...